Company Overview

Neurogene Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare neurological disorders. The company operates within the biotechnology and gene therapy industries, with an emphasis on diseases caused by single-gene mutations affecting the central nervous system. Its core strategy centers on using adeno-associated virus (AAV)-based vectors and proprietary regulatory elements to deliver durable genetic therapies directly to neural tissue.

Neurogene was founded in 2018 and is headquartered in the United States. The company’s development platform is designed to precisely control gene expression in the brain, which it positions as a key differentiator in addressing neurological diseases where overexpression can lead to toxicity. Neurogene became a publicly traded company in 2023 following an initial public offering, marking its transition from a privately funded research organization to a publicly accountable clinical-stage enterprise.

Business Operations

Neurogene’s operations are primarily organized around its gene therapy development programs, which focus on rare monogenic neurological conditions. The company does not currently generate commercial revenue and instead operates as a research- and development-driven organization. Its lead clinical programs target Rett syndrome and other neurodevelopmental or neurodegenerative disorders with significant unmet medical need, using AAV vectors administered directly to the central nervous system.

The company’s assets include its proprietary AAV gene therapy platform, preclinical research capabilities, and early-stage clinical trial infrastructure. Neurogene conducts most of its research and development through internal teams while also relying on external contract research organizations and manufacturing partners for clinical trial execution and vector production. As of publicly available disclosures, the company does not report material revenue-generating subsidiaries or joint ventures.

Strategic Position & Investments

Neurogene’s strategic direction is centered on advancing its clinical pipeline through early- and mid-stage trials while expanding the applicability of its regulated gene expression technology to additional neurological indications. Growth initiatives focus on progressing lead candidates into later-stage clinical development and leveraging platform learnings to build a broader portfolio of CNS-targeted gene therapies.

The company has invested heavily in research, clinical development, and intellectual property related to gene regulation and delivery in the brain. Its strategic positioning emphasizes safety and durability, particularly in contrast to earlier-generation gene therapies that lacked precise expression control. Public disclosures indicate no large-scale acquisitions to date; expansion has primarily occurred through internal development and targeted licensing of enabling technologies.

Geographic Footprint

Neurogene’s primary operations are based in the United States, where its corporate headquarters and core research functions are located. Clinical development activities are conducted predominantly in North America, with clinical trial sites selected based on disease expertise and patient availability.

While Neurogene does not maintain a broad international commercial presence, its clinical trials and research collaborations may involve investigators and service providers in international markets. The company’s geographic footprint remains relatively concentrated, consistent with its status as a clinical-stage biotechnology firm focused on advancing a limited number of highly specialized therapeutic programs.

Leadership & Governance

Neurogene is led by an executive team with experience in biotechnology, neuroscience, and clinical development. The leadership emphasizes a science-driven approach, prioritizing rigorous clinical validation, patient safety, and long-term therapeutic durability in neurological gene therapy.

Key executives include:

• Rachel McMinn – Founder and Chief Executive Officer
• Mark J. A. McDonald – Chief Financial Officer
• Daniel H. Geschwind – Co-Founder and Scientific Advisor
• Allison A. Willis – Chief Medical Officer

The company is governed by a board of directors with backgrounds in biotechnology, medicine, and capital markets, supporting oversight of strategy, risk management, and regulatory compliance as Neurogene advances its clinical pipeline.